These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

242 related articles for article (PubMed ID: 6721515)

  • 21. Comparison of anastrozole versus tamoxifen as preoperative therapy in postmenopausal women with hormone receptor-positive breast cancer: the Pre-Operative "Arimidex" Compared to Tamoxifen (PROACT) trial.
    Cataliotti L; Buzdar AU; Noguchi S; Bines J; Takatsuka Y; Petrakova K; Dube P; de Oliveira CT
    Cancer; 2006 May; 106(10):2095-103. PubMed ID: 16598749
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Experimental studies on the enhanced effects of chemoendocrine therapy in breast cancer].
    Abe R; Sawano A; Ueki H; Akimoto M; Kimura M
    Gan To Kagaku Ryoho; 1987 Mar; 14(3 Pt 2):785-92. PubMed ID: 3566291
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Chemoendocrine therapy for premenopausal women with axillary lymph node-positive, steroid hormone receptor-positive breast cancer: results from INT 0101 (E5188).
    Davidson NE; O'Neill AM; Vukov AM; Osborne CK; Martino S; White DR; Abeloff MD
    J Clin Oncol; 2005 Sep; 23(25):5973-82. PubMed ID: 16087950
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [A case of male breast cancer with special reference to the hormonal environment during chemoendocrine therapy].
    Saito K; Hotta T; Kobayashi S; Miura I; Sakuma S; Shimozato T; Torii T; Iwase H; Satake A; Nishida T
    Gan No Rinsho; 1985 Oct; 31(13):1727-30. PubMed ID: 3001383
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Progesterone receptor status of breast cancer metastases.
    Branković-Magić M; Janković R; Nesković-Konstantinović Z; Nikolić-Vukosavljević D
    J Cancer Res Clin Oncol; 2002 Jan; 128(1):55-60. PubMed ID: 11862473
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Microtubule-associated protein-tau is a bifunctional predictor of endocrine sensitivity and chemotherapy resistance in estrogen receptor-positive breast cancer.
    Andre F; Hatzis C; Anderson K; Sotiriou C; Mazouni C; Mejia J; Wang B; Hortobagyi GN; Symmans WF; Pusztai L
    Clin Cancer Res; 2007 Apr; 13(7):2061-7. PubMed ID: 17404087
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The nature of tamoxifen action in the control of female breast cancer.
    Kodama M; Kodama T
    In Vivo; 2001; 15(4):319-25. PubMed ID: 11695224
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Sex hormone dependency in diffuse carcinoma of the stomach and results of chemo-endocrine therapy].
    Kitaoka H
    Gan No Rinsho; 1984 May; 30(6 Suppl):741-8. PubMed ID: 6086975
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Metastatic breast cancers: comparison of the prognostic significance and the sensitivity to chemotherapy according to the presence of estradiol and progesterone receptors].
    Pouillart P; Madgelenat H; Jouve M; Palangie T; Garcia-Giralt E; Bretaudeau B; Polijcak M; Asselain B
    Bull Cancer; 1982; 69(5):461-7. PubMed ID: 7165808
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Proceedings of the symposium on antiestrogen therapy for hormone-dependent tumors, September 29, 1979, Sorrento, Italy.
    Cancer Treat Rep; 1980; 64(6-7):739-827. PubMed ID: 7427958
    [No Abstract]   [Full Text] [Related]  

  • 31. Tamoxifen, hormone receptors and hormone replacement therapy in women previously treated for breast cancer: a cohort study.
    Dew JE; Wren BG; Eden JA
    Climacteric; 2002 Jun; 5(2):151-5. PubMed ID: 12051110
    [TBL] [Abstract][Full Text] [Related]  

  • 32. American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for postmenopausal women with hormone receptor-positive breast cancer: status report 2004.
    Winer EP; Hudis C; Burstein HJ; Wolff AC; Pritchard KI; Ingle JN; Chlebowski RT; Gelber R; Edge SB; Gralow J; Cobleigh MA; Mamounas EP; Goldstein LJ; Whelan TJ; Powles TJ; Bryant J; Perkins C; Perotti J; Braun S; Langer AS; Browman GP; Somerfield MR
    J Clin Oncol; 2005 Jan; 23(3):619-29. PubMed ID: 15545664
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The NFkappaB pathway and endocrine-resistant breast cancer.
    Zhou Y; Eppenberger-Castori S; Eppenberger U; Benz CC
    Endocr Relat Cancer; 2005 Jul; 12 Suppl 1():S37-46. PubMed ID: 16113098
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Steroid receptors in human breast cancer.
    McGuire WL
    Cancer Res; 1978 Nov; 38(11 Pt 2):4289-91. PubMed ID: 698967
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Chemotherapy is more effective in patients with breast cancer not expressing steroid hormone receptors: a study of preoperative treatment.
    Colleoni M; Viale G; Zahrieh D; Pruneri G; Gentilini O; Veronesi P; Gelber RD; Curigliano G; Torrisi R; Luini A; Intra M; Galimberti V; Renne G; Nolè F; Peruzzotti G; Goldhirsch A
    Clin Cancer Res; 2004 Oct; 10(19):6622-8. PubMed ID: 15475452
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Primary endocrine therapy in locally advanced breast cancers--the Nottingham experience.
    Mathew J; Agrawal A; Asgeirsson KS; Buhari SA; Jackson LR; Cheung KL; Robertson JF
    Breast Cancer Res Treat; 2009 Jan; 113(2):403-7. PubMed ID: 18311583
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Beyond tamoxifen: extended and late extended endocrine therapy in postmenopausal early breast cancer.
    Dodwell D; Williamson D
    Cancer Treat Rev; 2008 Apr; 34(2):137-44. PubMed ID: 18006236
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prognostic value of Ki67 expression after short-term presurgical endocrine therapy for primary breast cancer.
    Dowsett M; Smith IE; Ebbs SR; Dixon JM; Skene A; A'Hern R; Salter J; Detre S; Hills M; Walsh G;
    J Natl Cancer Inst; 2007 Jan; 99(2):167-70. PubMed ID: 17228000
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [The clinical significance of hormone receptors in the treatment of breast cancer].
    Trams G
    Fortschr Med; 1979 Apr; 97(14):641-4. PubMed ID: 437632
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Factors affecting progression-free survival in hormone-dependent metastatic breast cancer patients receiving high-dose chemotherapy and hematopoietic progenitor cell transplantation: role of maintenance endocrine therapy.
    Montemurro F; Rondón G; Ueno NT; Munsell M; Gajewski JL; Champlin RE
    Bone Marrow Transplant; 2002 May; 29(10):861-6. PubMed ID: 12058236
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.